The MHRA’s validation of Nuvation Bio’s marketing authorisation application marks an important regulatory validation taletrectinib for adults with advanced ROS1-positive non-small cell lung cancer. This milestone, achieved via the International Recognition Procedure in parallel with EMA review, f...

Portuguese Biotech Innovation has matured into a compelling global force, with Solfarcos marking a decade of translating University of Minho research into commercial technologies that span cosmetics and pharmaceuticals. The Braga-based spin-off has built a unified platform of peptides and protein...

Portugal’s medicines regulator INFARMED has been shaken by a major case of cannabis regulatory exploitation in which criminal networks weaponised medicinal cannabis licences to traffic drugs on an industrial scale. Insufficient inspectors, rapid sector growth and the recruitment of former agency ...

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...